太平洋医药日报：阿斯利康BREZTRI三期临床成功

太平洋证券股份...2025-05-07

市场表现：2025 年5 月6 日，医药板块涨跌幅+1.07%，跑赢沪深300 指数0.06pct，涨跌幅居申万31 个子行业第24 名。各医药子行业中，医院(+2.17%)、医疗研发外包(+2.15%)、疫苗（+1.67%）表现居前，线下药店（-1.17%)、血液制品(+0.88%)、体外诊断（+1.08%)表现居后。个股方面，日涨幅榜前3 位分别为金凯生科(+20.01%)、常山药业(+...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533667622?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533667622","market":"us","top_or_hot":-1,"title":"太平洋医药日报：阿斯利康BREZTRI三期临床成功","media":"太平洋证券股份...","content":"<div>\n<p>市场表现：2025 年5 月6 日，医药板块涨跌幅+1.07%，跑赢沪深300 指数0.06pct，涨跌幅居申万31 个子行业第24 名。各医药子行业中，医院(+2.17%)、医疗研发外包(+2.15%)、疫苗（+1.67%）表现居前，线下药店（-1.17%)、血液制品(+0.88%)、体外诊断（+1.08%)表现居后。个股方面，日涨幅榜前3 位分别为金凯生科(+20.01%)、常山药业(+...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>太平洋医药日报：阿斯利康BREZTRI三期临床成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n太平洋医药日报：阿斯利康BREZTRI三期临床成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b><strong>太平洋证券股份...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>市场表现：2025 年5 月6 日，医药板块涨跌幅+1.07%，跑赢沪深300 指数0.06pct，涨跌幅居申万31 个子行业第24 名。各医药子行业中，医院(+2.17%)、医疗研发外包(+2.15%)、疫苗（+1.67%）表现居前，线下药店（-1.17%)、血液制品(+0.88%)、体外诊断（+1.08%)表现居后。个股方面，日涨幅榜前3 位分别为金凯生科(+20.01%)、常山药业(+...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b","article_id":"2533667622","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533667622","pubTimestamp":1746547200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"行业要闻：近日，阿斯利康宣布，三联吸入气雾剂Breztri在哮喘控制不佳患者中进行的两项3期临床试验KALOS 和LOGOS 中获得积极顶线结果。Breztri 是一种吸入式三联组合疗法，目前已在包括美国、欧盟、中国和日本在内的全球80 多个国家和地区获批用于治疗成人慢性阻塞性肺病。众生药业：公司发布公告，子公司众生睿创自主研发的RAY1225 注射液于近日获得减重和降糖两项II 期临床试验剂量扩展组的顶线分析数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","BK4568":"美国抗疫概念","BK4588":"碎股","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Pacific Pharmaceutical Daily: AstraZeneca BREZTRI Phase III clinical success","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"市场表现：2025 年5 月6 日，医药板块涨跌幅+1.07%，跑赢沪深300 指数0.06pct，涨跌幅居申万31 个子行业第24 名。各医药子行业中，医院(+2.17%)、医疗研发外包(+2.15%)、疫苗（+1.67%）表现居前，线下药店（-1.17%)、血液制品(+0.88%)、体外诊断（+1.08%)表现居后。个股方面，日涨幅榜前3 位分别为金凯生科(+20.01%)、常山药业(+11.89%)、莎普爱思(+10.05%)；跌幅榜前3 位为永安药业（-9.99%）、泽璟制药(-6.02%)、奥赛康（-5.80%)。行业要闻：近日，阿斯利康（AstraZeneca）宣布，三联吸入气雾剂Breztri（布地奈德/格隆溴铵/富马酸福莫特罗）在哮喘控制不佳患者中进行的两项3期临床试验KALOS 和LOGOS 中获得积极顶线结果。Breztri 是一种吸入式三联组合疗法，目前已在包括美国、欧盟、中国和日本在内的全球80 多个国家和地区获批用于治疗成人慢性阻塞性肺病（COPD）。（来源：阿斯利康，太平洋证券研究院）公司要闻：诺思格（301333）：公司发布公告，截至2025 年4 月30 日，公司通过回购专用证券账户以集中竞价交易方式已累计回购股份1,442,000 股，约占公司目前总股本96,581,256 股的1.49%，成交价格区间为35.06-43.15 元/股，成交总金额为56,062,734.00 元（不含交易费用）。众生药业（002317）：公司发布公告，子公司众生睿创自主研发的RAY1225 注射液于近日获得减重和降糖两项II 期临床试验剂量扩展组的顶线分析数据。数据表明，RAY1225 注射液3~9 mg 在中国成人肥胖/超重参与者和2 型糖尿病参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。老百姓（603883）：公司发布公告，为调整资产和融资结构，降低股票质押率， 公司控股股东老百姓医药集团计划合计减持不超过22,802,868 股，合计减持比例不超过总股本的3%，其中通过大宗交易减持总股本的2%，集中竞价交易减持总股本的1%。东诚药业（002675）：公司发布公告，子公司东诚北方收到国家药品监督管理局核准签发的关于注射用氢化可的松琥珀酸钠的《药品补充申请批准通知书》，东诚北方生产的注射用氢化可的松琥珀酸钠通过仿制药质量和疗效一致性评价。风险提示：新药研发及上市不及预期；市场竞争加剧风险等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533667622","isCrawlerRequest":true}